Every 8-K that Envoy Medical (COCH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow COCH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COCH filings page.
Envoy Medical, Inc. (COCH) appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026. He will continue to serve as the company’s principal financial officer and principal accounting officer, transitioning from his prior contractor role as Interim Chief Financial Officer.
Under an Employment Agreement dated August 24, 2026, Mr. Potashnick will receive a base salary of $315,000 per year, an initial target annual bonus equal to 15% of base salary based on performance goals, and an initial equity award of 250,000 stock options with an exercise price of $0.746 per share, matching the Class A common stock closing price on his hire date. The agreement includes six months of severance compensation in certain termination scenarios. The company states he has no related-party transactions requiring disclosure and no family relationships with directors or executive officers.
Envoy Medical, Inc. reported second-quarter 2026 results and highlighted progress toward commercializing its fully implanted Acclaim cochlear implant. The company submitted the first of four modules of its modular PMA application to the FDA and plans to submit remaining modules on a rolling basis, with the fourth targeted in the second quarter of 2027. Subsequent to quarter end, Envoy reported positive 12‑month data for the first 10 Stage 1 trial participants and noted that the pivotal trial has surpassed the three‑month follow-up mark.
For the quarter ended June 30, 2026, net revenue was $51,000. Net loss attributable to common stockholders was $7.3 million, or $0.07 per share. As of June 30, 2026, cash was $19.7 million, supported by $30.0 million of proceeds from an issuance of Class A common stock, pre‑funded warrants and Series A warrants during the first half of 2026. Total assets were $23.9 million and stockholders’ equity was $3.3 million.
Envoy Medical, Inc. has terminated its at-the-market equity facility, which had allowed the company to offer and sell up to $15 million of common stock from time to time. The termination, effective June 24, 2026, also ends the related At The Market Offering Agreement dated January 17, 2025.
The company framed this step as reflecting confidence in its current capital position. Existing Class A common stock and redeemable warrants continue to trade on Nasdaq under the symbols COCH and COCHW, respectively.
Envoy Medical updated its CEO compensation package. The board’s compensation committee approved a new base salary of $420,000 per year for Chief Executive Officer Brent Lucas, plus eligibility for a $105,000 target cash bonus tied to strategic goals for 2026 and 2027.
Lucas also received 1,000,000 stock options exercisable at $0.634 per share that vest over four years, and 1,000,000 restricted stock units. The RSUs will vest only if the FDA issues an approval, including conditional approval, for Envoy’s Acclaim cochlear implant during the period from June 19, 2026 to June 18, 2030.
Envoy Medical, Inc. reports that Nasdaq has granted an additional 180-day period, until November 16, 2026, to regain compliance with the Nasdaq Capital Market’s $1.00 minimum bid price requirement for its Class A common stock.
The company previously failed to meet this bid price by the initial May 18, 2026 deadline, after its shares traded below $1.00 for 30 consecutive business days. Envoy remains otherwise in compliance with Nasdaq Capital Market listing standards and has notified Nasdaq that it intends to cure the deficiency, including potentially implementing a reverse stock split if needed.
Envoy Medical, Inc. reported results of its 2026 Annual Meeting of Stockholders held on May 12, 2026. Stockholders approved amendments to the 2023 Equity Incentive Plan and the 2023 Employee Stock Purchase Plan.
The Equity Incentive Plan amendment authorizes an additional 6,000,000 shares of Class A Common Stock for awards, while the Employee Stock Purchase Plan amendment authorizes an additional 1,200,000 shares for employee purchases. Both amendments became effective upon stockholder approval.
Stockholders also elected Brent T. Lucas and Susan J. Kantor as directors, with each nominee receiving over 46.9 million votes "for" and modest withheld and broker non-vote totals, as detailed in the voting results.
Envoy Medical reported first quarter 2026 results and key milestones as it advances its fully implanted Acclaim cochlear implant toward FDA approval. Net revenue was $39,000, with an operating loss of $6.0 million and net loss of $4.4 million, or $0.08 per share attributable to common stockholders.
Cash rose to $25.3 million as of March 31, 2026, supported by an upsized public offering for up to $78.0 million, including $30.0 million in gross proceeds at closing and additional potential proceeds from milestone-linked warrants. The company completed enrollment of its U.S. pivotal trial, implanting the 56th and final patient, and early six‑month data from the first 10 patients showed no study-defined serious adverse events and improved CNC word recognition from 15.2% to 39.2%, supporting its path toward a planned PMA submission.
Envoy Medical, Inc. reported that its audit committee dismissed Grant Thornton LLP as its independent registered public accounting firm on March 25, 2026 and appointed EisnerAmper LLP to audit the fiscal year ending December 31, 2026.
Grant Thornton’s audit reports for the years ended December 31, 2025 and 2024 contained explanatory paragraphs expressing substantial doubt about Envoy Medical’s ability to continue as a going concern, but were not otherwise qualified or modified. The company states there were no disagreements with Grant Thornton and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting.
Envoy Medical reported full year 2025 results showing it is still early-stage but making strategic progress. Net revenue was $241,000, slightly up from $225,000, while operating expenses of $22.5 million and other items drove a net loss of $23.8 million and a net loss attributable to common stockholders of $28.7 million, or $1.23 per share.
The company strengthened its balance sheet by extinguishing about $32 million of related-party term loan debt, supported by a $27.9 million deemed capital contribution. Total liabilities were $20.3 million and stockholders’ deficit improved to $12.2 million as of December 31, 2025, with cash of $3.7 million.
Operationally, Envoy advanced its fully implanted Acclaim cochlear implant program, receiving FDA approval to expand its pivotal trial to its final stage in 2025 and subsequently completing enrollment. After year-end it closed what it describes as a transformational capital raise led by institutional healthcare investors, positioning it to continue development toward a planned PMA submission.
Envoy Medical, Inc. has regained compliance with the Nasdaq Capital Market’s continued listing standards. Nasdaq confirmed that the company now meets Listing Rule 5550(b)(2) after previously receiving a notice in February 2025 for not maintaining the required $35 million Market Value of Listed Securities.
The company attributes its renewed compliance to strategic financing initiatives that substantially strengthened its balance sheet and will remain under a one-year discretionary panel monitor starting February 12, 2026. Envoy Medical states it believes it has an achievable plan to stay in compliance and continue trading on Nasdaq under the symbol COCH.
Envoy Medical, Inc. completed an upsized public offering that raised approximately $30.0 million in gross proceeds by selling an aggregate of 75,000,000 shares of Class A common stock (or pre-funded warrants in lieu) plus milestone-linked Series A-1 and Series A-2 warrants to purchase up to 120,000,000 additional shares.
The warrants carry a $0.40 exercise price and become exercisable after stockholder approval, with earlier expirations tied to FDA milestones for the company’s Acclaim cochlear implant. If fully exercised for cash, the warrants could bring in about $48.0 million more. Envoy plans to use the net proceeds for working capital and to fund its pivotal FDA clinical study, and it expects the financing to extend its cash runway into the second half of 2027.
Envoy Medical, Inc. reported that its Compensation Committee approved new stock option grants for its Chief Executive Officer and Interim Chief Financial Officer under the company’s 2023 Equity Incentive Plan.
On February 5, 2026, CEO Brent Lucas received options to purchase 200,000 shares of Class A common stock, and Interim CFO Robert Potashnick received options for 15,000 shares. Both grants have an exercise price of $0.53 per share, matching the closing price on the Nasdaq Capital Market on the award date. Twenty‑five percent of each grant vests after one year, with the remaining options vesting pro rata over the following 36 months, and each award has a 10‑year term.
Envoy Medical, Inc. is providing an updated investor presentation that its management may use, with possible modifications, in meetings with current and potential investors. The presentation is attached as Exhibit 99.1 and includes forward-looking statements, with related risks and uncertainties described in the presentation. This information is being furnished under Regulation FD and is not deemed filed or incorporated into other securities law filings unless specifically referenced.
Envoy Medical, Inc. (COCH) reports that Nasdaq has notified the company its Class A common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, after trading below that level for 30 consecutive business days. The stock remains listed for now.
Envoy has 180 calendar days, until May 18, 2026, to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. If it qualifies, the company may receive an additional 180‑day period and could use measures such as a reverse stock split to address the deficiency. Failure to regain or maintain compliance could lead to a Nasdaq delisting determination, which Envoy could appeal. The company states it intends to monitor its share price and consider available options.
Envoy Medical (COCH) furnished an Item 2.02 Form 8-K announcing it issued a press release with financial results for its third fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The disclosure is furnished, not filed, and is therefore not subject to Section 18 liabilities or incorporation by reference.
Envoy Medical (COCH) received a Nasdaq compliance extension. The Nasdaq Hearings Panel granted the company an exception to satisfy the $35 million market value of listed securities requirement through February 23, 2026.
The company must promptly notify the Panel of any significant events that could affect meeting the exception’s terms. Envoy was first notified of noncompliance on February 25, 2025, did not regain compliance within the 180-day cure period, and presented its case at a hearing on October 2, 2025. On October 27, 2025, it issued a press release announcing the Panel’s decision.
Envoy’s Class A common stock trades on Nasdaq under COCH, and its redeemable warrants under COCHW.
Envoy Medical, Inc. entered into a financing in which it will sell 3,007,524 shares of Class A common stock in a registered direct offering at $1.33 per share, for expected gross proceeds of about $4.0 million before fees and expenses. At the same time, the company will issue Private Warrants in a concurrent private placement to purchase up to 9,022,572 additional shares at $1.33 per share, which could bring in about $12.0 million in additional gross proceeds if fully exercised in cash.
The Private Warrants are immediately exercisable and will expire two years after the resale registration for the warrant shares becomes effective. Envoy agreed to file a resale registration statement on Form S-1 within 30 days and to seek effectiveness within 90 days of closing. The company also granted H.C. Wainwright & Co. cash fees on the offering and warrant exercises and issued it Placement Agent Warrants for up to 225,564 shares at an exercise price of $1.6625 per share. Envoy plans to use the net proceeds for working capital and general corporate purposes.
Envoy Medical, Inc. filed a current report describing a regulatory milestone for its fully implanted Acclaim® cochlear implant. The company announced that the U.S. Food and Drug Administration approved the expansion of its pivotal clinical trial for Acclaim to the final stage. This means the study can now move into its concluding phase under FDA authorization, an important step in the product’s clinical development.
Envoy Medical, Inc. entered into a securities purchase agreement for a registered direct offering of 1,908,402 shares of Class A common stock at $1.31 per share, expected to generate approximately $2.5 million in gross proceeds. In a concurrent private placement, the company will issue Private Warrants to purchase up to 5,725,206 additional shares at an exercise price of $1.31 per share, exercisable after required stockholder approval and expiring 24 months after that approval.
The company must obtain stockholder approval within 90 days of closing and, if needed, call additional meetings every 90 days until approval is obtained or the Private Warrants lapse. Envoy agreed to file a Form S-1 to register the resale of Warrant Shares within 30 days and to keep it effective while Purchasers hold Private Warrants or Warrant Shares. The company is subject to a 30-day equity lock-up and a one-year prohibition on variable rate transactions, and will pay H.C. Wainwright & Co. cash fees of 8.5% of gross proceeds plus expense reimbursements and issue Placement Agent Warrants for up to 143,130 shares at $1.6375 per share.
Envoy Medical, Inc. filed a current report to disclose that it has received a European patent titled “Implantable Cochlear System with Integrated Components and Lead Characterization.” This patent relates to the company’s implantable cochlear system technology.
The company announced the patent in a press release dated September 19, 2025, which is included as Exhibit 99.1 to the report and incorporated by reference.
Envoy Medical, Inc. disclosed that it and certain related parties entered into a Voting and Warrant Extension Agreement dated September 4, 2025. The agreement extends the expiration date of warrants held by GAT Funding, LLC and related Taylor parties to December 31, 2028. Prior to the extension those warrants had staggered expirations between February 27, 2026 and June 26, 2027.
The filing identifies Glen A. Taylor and affiliated entities as the warrant holders and notes Mr. Taylor directly or indirectly owns approximately 47.8% of the Company’s outstanding Class A Common Stock. The document is filed on Form 8-K and includes the Voting and Warrant Extension Agreement as an exhibit.
Envoy Medical, Inc. reports that Nasdaq has determined the company is not back in compliance with the minimum market value of listed securities requirement of $35,000,000 after a 180-day cure period that followed an earlier deficiency notice tied to trading between January 7 and February 24, 2025. On August 26, 2025, Nasdaq issued a determination letter stating the company had not regained compliance and outlining that trading in its securities could be suspended and a Form 25-NSE filed to delist them.
The company requested a hearing with a Nasdaq Hearings Panel on August 29, 2025, which temporarily prevents any trading suspension or Form 25-NSE filing until after the panel meets and issues a decision. Envoy Medical indicates it is optimistic about presenting several relatively near-term paths to regain compliance, including a recent full extinguishment of its debt, but cautions there is no assurance that continued listing or an extension will be granted.
Envoy Medical, Inc. filed an 8-K reporting the satisfaction of promissory notes between the company and GAT Funding, LLC, effective August 25, 2025. The filing references termination of a material definitive agreement and notes related disclosure items for director or officer changes without providing specific names or details in the text provided.
The filing lists the company's securities (Class A Common Stock, COCH; Redeemable Warrants, COCHW) and attaches a press release dated August 26, 2025. The document is signed by Brent T. Lucas, Chief Executive Officer.
Envoy Medical (NASDAQ:COCH) announced the appointment of Robert Potashnick as Interim Chief Financial Officer, effective June 23, 2025. Potashnick, 45, will serve as the company's principal financial officer and principal accounting officer through his consulting entity Oasis Business Consulting LLC. He brings significant experience from previous CFO roles at Flutterbee Education Group and FOXO Technologies, along with positions at UnitedHealth Group and PricewaterhouseCoopers LLP. The appointment is structured through a Consulting Agreement on a fractional consultant basis.